Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity
Authors:
- Shih-Yu ChangSCShih-Yu Chang
- Elijah J. WeberEWElijah J. Weber
- Viktoriya S. SidorenkoVSViktoriya S. Sidorenko
- Alenka ChapronACAlenka Chapron
- Chunying GaoCGChunying Gao
- Qingcheng MaoQingcheng Mao
- Danny ShenDSDanny Shen
- Joanne WangJWJoanne Wang
- Thomas A. RosenquistTRThomas A. Rosenquist
- Kathleen G. DickmanKDKathleen G. Dickman
- Thomas NeumannTNThomas Neumann
Open Access
- 16 November 2017
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 2 (22)
Abstract
Environmental exposures pose a significant threat to human health. However, it is often difficult to study toxicological mechanisms in human subjects due to ethical concerns. Plant-derived aristolochic acids are among the most potent nephrotoxins and carcinogens discovered to date, yet the mechanism of bioactivation in humans remains poorly understood. Microphysiological systems (organs-on-chips) provide an approach to examining the complex, species-specific toxicological effects of pharmaceutical and environmental chemicals using human cells. We microfluidically linked a kidney-on-a-chip with a liver-on-a-chip to determine the mechanisms of bioactivation and transport of aristolochic acid I (AA-I), an established nephrotoxin and human carcinogen. We demonstrate that human hepatocyte-specific metabolism of AA-I substantially increases its cytotoxicity toward human kidney proximal tubular epithelial cells, including formation of aristolactam adducts and release of kidney injury biomarkers. Hepatic biotransformation of AA-I to a nephrotoxic metabolite involves nitroreduction, followed by sulfate conjugation. Here, we identify, in a human tissue-based system, that the sulfate conjugate of the hepatic NQO1-generated aristolactam product of AA-I (AL-I-NOSO 3 ) is the nephrotoxic form of AA-I. This conjugate can be transported out of liver via MRP membrane transporters and then actively transported into kidney tissue via one or more organic anionic membrane transporters. This integrated microphysiological system provides an ex vivo approach for investigating organ-organ interactions, whereby the metabolism of a drug or other xenobiotic by one tissue may influence its toxicity toward another, and represents an experimental approach for studying chemical toxicity related to environmental and other toxic exposures.Keywords
Funding Information
- Norges Idrettshøgskole (NIEHS P30ES07033)
- Norges Idrettshøgskole (NCATS 5UH3TR000504)
- U.S. Environmental Protection Agency (83573801)
- Norges Idrettshøgskole (NCATS 5UH3TR000504)
This publication has 42 references indexed in Scilit:
- How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory ToxicologyToxicological Sciences, 2016
- Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I andN-hydroxyaristolactam I in human cellsCarcinogenesis, 2016
- Aristolochic Acid I Metabolism in the Isolated Perfused Rat KidneyChemical Research in Toxicology, 2011
- Mammalian multidrug-resistance proteins (MRPs)Essays in Biochemistry, 2011
- NTP 12th Report on Carcinogens.2011
- Assessment of the Role of Renal Organic Anion Transporters in Drug-Induced NephrotoxicityToxins, 2010
- The current state of serum biomarkers of hepatotoxicityToxicology, 2008
- Human sulphotransferases are involved in the activation of aristolochic acids and are expressed in renal target tissueInternational Journal of Cancer, 2005
- Human Organic Anion Transporter 4 Is a Renal Apical Organic Anion/Dicarboxylate Exchanger in the Proximal TubulesJournal of Pharmacological Sciences, 2004
- Misuse of Herbal Remedies: The Case of an Outbreak of Terminal Renal Failure in Belgium (Chinese Herbs Nephropathy)The Journal of Alternative and Complementary Medicine, 1998